LEXINGTON, MASSACHUSETTS, U.S.A., April 16, 2009 – RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced the commercial sale of an RDT 1000 and Sequence Enrichment Solution to Expression Analysis, Inc., a leading provider of genomic services for clinical trials and research.
The RainDance solution will enable Expression Analysis to expand its service offerings to provide genomic researchers quality and efficient targeted sequencing on large sample numbers.
“As the market leader in genomic outsourcing for gene expression, genotyping, and resequencing analysis, we enable our service offerings using best-in-class systems. RainDance Technologies is clearly in this class, and we are proud to incorporate their technology to further expand our suite of services and look forward to offering expanded DNA sequencing applications,” said Steve McPhail, President and Chief Executive Officer of Expression Analysis.
The announcement marks the first sale of the RainDance solution to a service provider. The solution consists of an RDT 1000, consumables kits, custom PCR primer libraries, and expert training.
“As a leading genomic service provider, Expression Analysis’ decision to embrace our platform accelerates the ability of researchers to access our sequence enrichment technology,” said Christopher McNary, President and Chief Executive Officer of RainDance Technologies.
The RDT 1000 and Sequence Enrichment Solution utilize RainDance’s breakthrough RainStorm™ microdroplet-based technology platform. The simplicity and speed of the technology are designed to maximize the efficiency of next-generation DNA sequencing workflows. The RDT 1000 generates picoliter-volume PCR reactions at the rate of 10 million discrete reactions per hour. The high-speed sample processing is further enhanced by the fact that the Sequence Enrichment Solution utilizes a library of PCR primers in droplets, enabling the amplification of hundreds to thousands of genomic loci in a single tube. The RainStorm format avoids the limitations of traditional multiplex hybridization and amplification technologies. RainDance’s solution minimizes process-induced bias or error and requires only a few micrograms of genomic DNA.
The commercial version of the Sequence Enrichment Solution is now being shipped in North America and will soon be available for shipment to Europe. For more information, contact , call 781-861-6300, or visit the company’s website at www.raindancetech.com.
About RainDance Technologies
RainDance Technologies is pioneering the use of high-throughput microdroplet-based analysis in human health and life science research. The company’s core RainStorm™ technology generates millions of discrete droplets that can encapsulate a single molecule, cell or reaction and be digitally analyzed and sorted one at a time. The power, precision and simplicity of microdroplets enable researchers to answer complex questions with unprecedented sensitivity and quantitation. The complete RainDance solution includes automated instrumentation, customizable bioinformatics and high-value consumables and reagents for applications including targeted next-generation DNA sequencing, methylation, digital PCR and single cell analysis. Based in Lexington, Massachusetts, the company supports scientists around the world through its international sales and support operations and a global network of distributors and service providers. For more information, please visit www.RainDanceTech.com.
RainDance, RainStorm, ThunderStorm, Digital Biology are trademarks of RainDance Technologies, Inc. All other brands may be trademarks of their respective holders.
About Expression Analysis, Inc.
Expertise Beyond Expression — Providing whole genome to focused set gene expression and genotyping assays, along with sequencing services using RainDance Technologies, Illumina, Affymetrix, and Applied Biosystems. A leading provider of genomic services in clinical trials and research, Expression Analysis offers solutions for challenging specimens such as blood and FFPE tissue specimens as well as nucleic acid isolation and bioinformatic services. The company’s quality system follows CLSI guidelines and their CLIA-registered lab supports GLP compliance.